Retatrutide, a novel dual stimulator of the GLP-1 target and glucose-dependent released polypeptide (GIP) receptor , is exhibiting promising results in early patient trials . Current inquiry suggests that https://bookmarkalexa.com/story7045358/retatrutide-emerging-research-and-potential-therapeutic-uses